What is prostaglandin E1 (PGE1) and how is it used clinically?

What is PGE1 (Prostaglandin E1)?

Prostaglandin E1 (PGE1), also known as alprostadil, is a synthetic vasodilator prostaglandin that causes smooth muscle relaxation and inhibits platelet aggregation by activating adenylyl cyclase and increasing cyclic adenosine monophosphate (cAMP) levels. 1, 2

Mechanism of Action

PGE1 works through multiple pathways:

• Vascular effects: Causes direct relaxation of smooth muscle cells in blood vessels and cavernous bodies 3, 4
• Platelet inhibition: Prevents platelet aggregation and reduces low-density lipoprotein entry into vascular walls 3
• Neurotransmitter modulation: Attenuates presynaptic noradrenaline release 2, 3
• Erectile function: Induces erection by relaxing trabecular smooth muscle and dilating cavernosal arteries, leading to expansion of lacunar spaces and compression of venules against the tunica albuginea (corporal veno-occlusive mechanism) 2

Clinical Applications

Erectile Dysfunction (FDA-Approved)

Intracavernous injection therapy with alprostadil is the most effective non-surgical treatment for erectile dysfunction, with response rates exceeding 70%. 5, 3, 6

• Initial dosing: The first dose must be administered under direct healthcare provider supervision to establish effective dosing (typically 10-20 mcg), monitor for priapism, and teach proper injection technique 5, 7, 2
• Hypotension risk: Approximately 3% of patients experience hypotension, particularly after the first dose 5, 8
• Priapism risk: Occurs in only 0.35% of patients with PGE1 compared to 6% with papaverine/phentolamine combinations 3
• Common side effects: Pain at injection site or during erection (16.8%), hematoma/ecchymosis (1.5%), and prolonged erection/priapism (1.3%) 6

Intraurethral alprostadil suppositories are a less invasive alternative but less effective than intracavernous injection 5

Peripheral Arterial Disease (Not FDA-Approved in US)

For intermittent claudication, oral vasodilator prostaglandins including PGE1 are NOT recommended as they are not effective medications to improve walking distance (ACC/AHA Class III recommendation, Level of Evidence: A). 1

• Intravenous PGE1 administered once or twice daily for 4-8 weeks showed some improvement in pain-free walking distance in trials, but daily IV administration is impractical for most patients 1

Critical Limb Ischemia

Parenteral administration of PGE-1 for 7-28 days may be considered to reduce ischemic pain and facilitate ulcer healing in patients with critical limb ischemia who are not candidates for revascularization, but efficacy is likely limited to a small percentage of patients (ACC/AHA Class IIb recommendation, Level of Evidence: A). 1

• Dosing: 60-80 micrograms over 2-4 hours per day for 7-28 days 1
• Efficacy: The largest trial (1560 patients) showed statistically significant but marginal improvement in ischemic pain and ulcer healing at 6 months, with no significant reductions in amputation or mortality risk 1
• Common adverse effects: Headache, flushing, and gastrointestinal distress 1

Congenital Heart Disease (Neonatal Use)

PGE1 maintains ductal patency in critical congenital heart disease 9

• Standard dosing: 0.05 µg/kg/minute, though lower doses (0.01 µg/kg/minute) have proven safe and effective in 83% of patients 9
• Respiratory depression: Occurs in 28% of patients, with mechanical ventilation needed in 8%, primarily in premature infants 9
• Prolonged use caution: Necrotizing vasculitis and pulmonary vascular changes have been reported with prolonged PGE1 administration in infants 10

Erythromelalgia

Intravenous iloprost (a synthetic prostacyclin analogue similar to PGE1) significantly reduces symptoms and sympathetic dysfunction in erythromelalgia, though oral misoprostol (a synthetic oral PGE1 analogue at 0.4-0.8 mg daily) should generally be considered first due to easier administration. 11

Pharmacokinetics

• Metabolism: Approximately 80% metabolized in one pass through the lungs, primarily by beta- and omega-oxidation 2
• Excretion: Almost 90% excreted in urine within 24 hours as metabolites 2
• Protein binding: 81% bound to albumin, 55% to α-globulin IV-4 fraction 2
• Systemic absorption: Following intracavernous injection of 20 mcg, peripheral plasma concentrations remain near baseline endogenous levels 2

Critical Safety Considerations

For Erectile Dysfunction Use

• Never prescribe for home use without in-office dose titration and supervised technique demonstration 7
• Maximum frequency: Once per 24-hour period 7
• Priapism protocol: Patients must seek immediate medical attention for erections lasting more than 4 hours; intracavernosal phenylephrine is the recommended initial treatment 7
• Cardiovascular monitoring: Blood pressure monitoring is mandatory during initial administration, especially in patients with pre-existing cardiovascular disease 8

Contraindications

• Sickle cell anemia, severe coagulopathy, schizophrenia or severe psychiatric disorder, poor manual dexterity, severe venous incompetence, or severe systemic disease 6

Long-Term Monitoring

• Monitor for penile fibrosis (incidence ranges from <1% to 23.3% depending on examination rigor) and angulation with extended use 12, 6
• If fibrosis develops, over half of cases improve spontaneously; watchful waiting with 3-month follow-up intervals is recommended 12